As part of the mission of the Rush Cartilage Restoration Center, orthopaedic surgeons at Rush are committed to providing patients with the full range of contemporary treatment options, including the latest minimally invasive procedures. Below is a brief description of a variety of ongoing research studies. If you would like more information about them, you can feel free to call the office or inquire about them at your next visit. All research studies have been approved by the Institutional Review Board at Rush-Presbyterian-St. Luke's Medical Center. Involvement in any fashion is purely elective and patients will undergo a thorough informed consent process. Patient information is strictly confidential and will only be used for research purposes.
The Cartilage Restoration Center at Rush University Medical Center, under the Direction of Dr. Brian J. Cole, is in its 14th year. Over the last decade, we have collected data and reported on more than 1,000 transplants and cartilage repair procedures. These publications and the rehabilitation protocols that you might find helpful for your practice are available in the Resource Library.
Below is a brief description of our ongoing clinical trials as they relate to the knee. If you believe you or your patients might qualify for these clinical trials or wish to have evaluated, please contact our research administrator, Mukesh Ahuja at 312-563-2214 or email@example.com. As always, I will make myself available at firstname.lastname@example.org.
Prospective Studies: For patients scheduled to have one of the following procedures, we encourage you to participate in regularly scheduled follow-up visits (6-month, 1-year, 2-year, 3-year). Your progress will be carefully monitored through self-assessment and physical examination. Many of these procedures are relatively new, and prospective studies may contribute to the management of these and other related conditions.
CARTILAGE TRIALS AT RUSH
Male and non-pregnant female patients between 18 and 60 years of age are screened for study recruitment. This is a five-year study and clinical evaluations will be performed preoperatively and postoperatively at 6 weeks, 6, 12, 18, 24, 36 months and annually thereafter through 5 years. Pre- and postoperative radiographs and MRIs will be performed.
Having completed the pre-clinical work and Phase I study at Rush, the FDA has approved the enrollment for a pivotal Phase III clinical trial. This is a prospective randomized study compared to microfracture for isolated defects of the femur. The purpose of this phase III clinical trial is to demonstrate the efficacy and safety of the CAIS implant for the treatment of non-OCD lesions (between ICRS grades I and IIID) or OCD lesions (between ICRS grades I and IVA) of the knee compared to microfracture treatment.
Male and non-pregnant female patients between 18 and 55 years of age are screened for study recruitment. This is a four-year study and clinical evaluations will be performed preoperatively and postoperatively at 1 & 3 weeks, 3, 6, 12, 18, 24, 30, 36, 42 and 48 months. Pre and postoperative radiographs and MRIs will be performed.
LIMITED RESURFACING IMPLANTS
HEMICAP RESURFACING PROSTHESIS
This is a prospective, non-randomized, open label pivotal clinical trial to evaluate the safety and efficacy of the HemiCAP Resurfacing Prosthesis for the treatment of focal femoral condyle defects. The clinical indication is limited to those individuals with significant pain and loss of joint function associated with large unstable full thickness articular (ICRS Grade 4) and osteochondral defects who have not responded to other treatments including previous cartilage repair surgery.
Male and non-pregnant female patients between 35 and 60 years of age are screened for study recruitment. This is a two-year study and clinical evaluations will be performed preoperatively and postoperatively at 2 & 6weeks, 3, 6, 12 and 24 months. Pre and postoperative MRIs will be performed.
MENISCAL TEAR WITH OA RESEARCH (MeTeOR)
The principal goals of the trial are:
The trial cohort will be followed for two years to examine differences in the efficacy of APM as compared with nonoperative therapy over a longer period of follow-up. Patients will be scheduled for a baseline evaluation, an intervention, and two follow-up evaluations at 3 and 18 months. The total duration of participation will be two years for each patient.
AUTOLOGOUS CONDITIONED PLASMA (ACP) vs. HYALURONIC ACID (HA)
The purpose of this randomized, double-blind, prospective trial is to investigate the use of ACP in patients with knee osteoarthritis and compare clinical & biological responses of ACP to current standard treatment, Hyaluronic-Acid. Over the course of 36 months, 100 patients will undergo synovial fluid aspiration at the time of injection, subjective questionnaires, physical-examination and imaging at set time-points to determine the effects of each treatment.
Inclusion criteria for this study will include patients between the ages of 18-80 with an image verified diagnosis of OA and symptomatic pain for at least one month with no recent treatment using intra-articular injections of the knee (i.e., corticosteroids or HA). Patients will be scheduled to receive injection once a week for three consecutive weeks and evaluations will be performed at baseline, week 1, 2 & 5 and month 3 & 6. The total duration of participation will be 6 months for each patient.
Can Platelet-Rich Plasma Ease the Pain of Osteoarthritis?
CHICAGO—For years, doctors have used platelet-rich plasma, or PRP, to promote healing after surgery. Now, Rush University Medical Center is studying whether PRP can help relieve knee pain in patients with mild to moderate osteoarthritis. PRP contains growth factors that promote cell proliferation and is prepared from the patient's own blood tissue. It has received popular attention because of its use in treating sports injuries in professional athletes, but the jury is still out on whether it is effective.
"There have been few controlled clinical trials, and results are inconsistent, but data so far suggests that it could be a promising treatment for healing in a variety of tissues," said Dr. Brian Cole, orthopaedic surgeon and head of the cartilage restoration center at Rush. "The therapy will not be a cure for osteoarthritis, but it could help put off the day when a patient will need to get a knee implant." At present, the standard of care is either corticosteroid injections, which may last about three months, or synthetic lubricants containing hyaluronic acid, which can last for up to a year.
In the double-blind, randomized, controlled study, 100 patients will receive either hyaluronic acid or PRP. The PRP is prepared from 10 millimeters of the patient's own blood. The blood is spun in a centrifuge to separate the platelets from the red and white blood cells. The platelets are then injected into the knee joint using ultrasound imaging to guide placement.
Patients will receive three injections over three weeks, and will be monitored for two years receiving a clinical exam to assess pain and knee function. In addition, a teaspoon-size sample will be taken of the synovial fluid around the knee joint to test for molecular changes that may indicate a shift in the balance of anabolic factors that increase the buildup of tissue and catabolic factors that break it down. An imbalance in these factors has been implicated in the deterioration that leads to osteoarthritis.
Arthroscopic Rotator Cuff Repair
Prospective Study: For patients scheduled to have arthroscopic rotator cuff repairs, we encourage you to participate in regularly scheduled follow-up visits (6-month, 1-year, 2-year, 3-year). Your progress will be carefully monitored through self-assessment and physical examination. This procedure is relatively new, and the prospective studies may contribute to the management of this and related conditions.
Normal Shoulder Function: A survey is performed that includes subjective and objective data to quantify shoulder function. We believe that there are a few variables that may influence the outcome of the score, namely age, sex, and hand dominance. We are currently collecting data from patients with normal shoulders to create a database sufficient to describe normal shoulder function to better understand disease processes.
Copyright 2001-2013 © Cartilagedoc.org, All Rights Reserved
Brian J. Cole, MD, MBA
of Orthopaedics and
Anatomy and Cell Biology
Division of Sports Medicine
Section Head, Cartilage Restoration Center at Rush
Rush University Medical Center
ABOUT DR. COLE
ABOUT OUR STAFF